Cell News and Research

RSS

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

The ALS Therapy Development Institute and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

17 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

SBRT improves survival in patients with inoperable non-small cell lung cancer

Highly-focused stereotactic body radiation therapy (SBRT) can eliminate the targeted tumor while avoiding treatment-related illness and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to early findings of a Radiation Therapy Oncology Group study published in the March 17 cancer-themed issue of the Journal of the American Medical Association.

17 Mar 2010

SBRT may improve survival rates for lung-cancer patients: Study

A radiation therapy that uses multiple radiation beams to target tumors precisely has been shown to eliminate the primary tumor and ultimately may improve survival rates for lung-cancer patients unable to undergo surgery, according to UT Southwestern Medical Center physicians who led a national clinical trial of the treatment.

17 Mar 2010

IRIS International announces the launch of new and improved corporate website

IRIS International, Inc., a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today the launch of its new and improved corporate website at www.proiris.com, featuring a newly designed homepage and enhanced navigation tools with access to the latest company information.

17 Mar 2010

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.

17 Mar 2010

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

17 Mar 2010

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

Ingenuity Systems, the leading provider of information solutions for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece, Turkey and the Balkan countries. IPA is the leading software application to model, analyze, and understand the complex biological and chemical systems at the core of life science research.

17 Mar 2010

BeaconEquity.com: CTIC' total net operating expenses for fourth-quarter of 2009 are $26.2M

BeaconEquity.com announces an investment report featuring Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

17 Mar 2010

Cord Blood America produces new edition of Corporate Profile

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ), focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced its has produced a new edition of Corporate Profile, which is used to answer inquiries about the Company from brokers, investors and other interested individuals.

17 Mar 2010

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

Reversal of aging in normal human cells

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced the publication of a scientific paper titled “Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcriptional Reprogramming.”

17 Mar 2010

Most controversial issues in urology to be discussed in the Annual Congress of EAU

Some of the most controversial issues in urology will be discussed by leading experts during the five-day 25th Annual Congress of the European Association of Urology in the Fira Barcelona congress venue in Barcelona (ES). From April 16 to 20, close to 12,000 participants and 3,000 company representatives are expected to gather in one of the world's biggest annual professional meetings in urology.

17 Mar 2010

Restoring immune function in HIV patients: Therapies targeting PD-1 and IL-10 molecules needed

New research conducted by the scientific director for VGTI Florida and his colleagues at the University of Montreal, in collaboration with scientists from the NIH and the McGill University Hospital center, may soon lead to an expansion of the drug arsenal used to fight HIV. The research sheds new light on how HIV gradually weakens the body’s immune system and highlights the need for new research into therapies that will target the chain of events that cause the progression of the disease.

17 Mar 2010

Avid Bioservices highlights data of single-use bioreactors and traditional stainless steel bioreactors

Avid Bioservices, Inc. today presented data highlighting the comparability of production run performance between the company's single-use bioreactors (Thermo Scientific HyClone S.U.B.) and its traditional stainless steel bioreactors at the Thermo Scientific BioProduction Optimization Workshop in San Francisco, California.

From Thermo Fisher Scientific Inc. 17 Mar 2010

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.

17 Mar 2010

Researchers identify a novel way to study species-specific reproductive behavior

Researchers at the California Institute of Technology (Caltech) and the University of California, San Diego (UCSD) have discovered that injecting a simple hormone into leeches creates a novel way to study how hormones and the nervous system work together to produce species-specific reproductive behavior.

17 Mar 2010

Radiofrequency ablation helps prolong life of colorectal cancer patients

Approximately half of Americans living with colorectal cancer will develop liver metastases at some point during the course of their disease. Radiofrequency ablation, a minimally invasive treatment that applies heat directly in the tumor causing cancer cell death with minimal associated injury to the surrounding healthy liver, contributes to prolongation of their life by nearly three years, note researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Cell News and Research

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

SBRT improves survival in patients with inoperable non-small cell lung cancer

SBRT may improve survival rates for lung-cancer patients: Study

IRIS International announces the launch of new and improved corporate website

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

BeaconEquity.com: CTIC' total net operating expenses for fourth-quarter of 2009 are $26.2M

Cord Blood America produces new edition of Corporate Profile

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

Reversal of aging in normal human cells

Most controversial issues in urology to be discussed in the Annual Congress of EAU

Restoring immune function in HIV patients: Therapies targeting PD-1 and IL-10 molecules needed

Avid Bioservices highlights data of single-use bioreactors and traditional stainless steel bioreactors

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Researchers identify a novel way to study species-specific reproductive behavior

Radiofrequency ablation helps prolong life of colorectal cancer patients

How to optimize your cell line development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo